Trailing Twelve Months Revenue Growth: LakeShore Biopharma Co. (LSB)

Graphic logo of YS Biopharma Co., Ltd. (LSB)

LakeShore Biopharma Co. (LSB) is fighting for survival amid internal conflicts and the abandonment of mergers, focusing instead on rabies vaccine sales. The year-over-year relative revenue growth rate (12 months) visualizes these challenges, with the current figure standing at . Risks are mitigated by outsourcing production and marketing in China to partners, as well as an advanced cold-chain logistics network that ensures high margins.

YS Biopharma (LSB) - Sales Growth YoY (Last Twelve Months) from 07/04/2022 to 11/18/2026

ysbiopharm.com (LSB) - metric breakdowns and financial figures

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:LSB (YS Biopharma)
Manufactured products of LakeShore Biopharma Co.

LakeShore Biopharma Co. (LSB) maintains a narrow specialization in rabies vaccines, rendering its revenue dependent on Chinese government procurement. This dependency is directly reflected in the year-over-year (TTM) commercial revenue growth trend, which smooths quarterly gaps via a rolling window. This metric measures the pace of business expansion, revealing hidden stagnations or sales accelerations. Trend analysis allows for the differentiation of temporary dips from a systemic demand crisis. By studying the year-over-year (TTM) commercial revenue growth, an investor assesses the resilience of cash flow against regulatory risks.